FDA Approves Zanidatamab for HER2-Positive Biliary Tract Cancer After Prior Treatment

The Food and Drug Administration (FDA) has approved zanidatamab for the treatment of HER2-positive biliary tract cancer. This approval offers a new therapeutic option for patients with this specific type of cancer. Zanidatamab is now available for patients whose cancer is HER2-positive and who have previously undergone treatment. Biliary tract cancer includes cancers of the gallbladder and bile ducts. The FDA’s decision is based on clinical trial data that demonstrated the drug’s effectiveness in this patient population.

Newsflash | Powered by GeneOnline AI
Date: April 24, 2025

Related posts:

Virginia’s Insurance Marketplace Extends Open Enrollment Deadline: A Detailed Report Cryptic Antigen Identified as New Immunotherapy Target for Ovarian Cancer Groundbreaking Study Reveals How Aging Heart Influences Brain Function Imaging Discovery Promises Faster Drug Development

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後